Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European Commission. Ikervis is approved for treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. The drug was produced based on an invention by Prof. Simon Benita of the Hebrew University's Instuitute for Drug Research.
The invention to be presented at Agritech Israel 2015
The licensed intellectual property is the result of many years of research and collaboration between renowned cannabinoid scientists, Raphael Mechoulam, Professor of medicinal chemistry, and Ruth Gallily, Professor of immunology, both from the Hebrew University; the distinguished immunologist, Professor Sir Marc Feldman, Director of the Kennedy Institute of Rheumatology; and prominent physicians and scientists at Hadassah Professors Chaim Lotan and Ronen Durst, and Dr. Lola Weiss.
Phytotech Medical went public on the Australian Securities Exchange raising AUS$5.9 million dollars
Prize awarded for contribution to collaboration between Melodea and Holmen
Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem, announced today that it has received US $3 million investment from Guangxi Wuzhou Pharmaceutical Group Co., Ltd., a subsidiary of the Guangxi Wuzhou Zongheng Group, a Chinese investment holdings company. The funds raised will be used to advance Integra Holdings’ existing portfolio companies and to create new companies, based on promising projects originating from the Hebrew University.
Yaacov Michlin, CEO of Yissum, said at the signing ceremony: “The framework agreement we signed today sets the ground for a wide range of potential areas of research collaboration between the two parties”.
The capital is intended for the on-going Phase 2b clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; next interim analysis is expected in Q3 2015; final results expected in Q3 2016
Funds will be used to advance development of AB103, a novel therapy for the treatment of necrotizing soft tissue infections
Avi Hasson, Chief Scientist of Israel’s Ministry of Economy, said at the award ceremony: ”Qlight Nanotech encompasses a winning combination of outstanding technology originating from the Hebrew University together with a leading international industry partner”
Novel sodium-ion battery is an environmentally friendly, economic and efficient solution for a variety of applications including electric vehicles and stationary storage for renewable energies
Yissum presents new oxidation-resistant copper nano-inks with a low sintering temperature (lower than 150oC), which enables the printing of low-cost conductive patterns on heat sensitive plastic substrates. Due to these traits, the new inks, developed by Prof. Shlomo Magdassi, from the Institute of Chemistry and the Center for Nanoscience and Nanotechnology can be tailored for a variety of applications, including ink-jet, flexography and screen printing.
The technology uses certain bacteria as novel bio-filters to reduce nitrate levels in both fresh-water and sea-water aquariums.
The novel polymer-clay composites have a higher pollutant removal capacity in comparison to activated carbon (the most common sorbent). The technology will be presented at the WATEC Conference, to be held in Tel Aviv, Israel on October 22-24, 2013.
The announcement was made at the opening of the new site of Qlight at the Edmond J. Safra Givat Ram Campus of the Hebrew University of Jerusalem in the presence of a senior management delegation from Merck headed by Dr. Bernd Reckmann, Member of the Executive Board, and in the presence of Mr. Nir Barkat, Mayor of Jerusalem, and Prof. Ben-Sasson , Hebrew University President and other dignitaries. [Hebrew PR]
The invention is based on a machine-learning algorithm that predicts the next outgoing call.
Novel biocontrol agent is environmentally-friendly, non-toxic and effective for a large variety of plants.
A novel method for detecting retinal micro-aneurysms that pose a high risk for leakage, an underlying cause of diabetic retinopathy. Diabetic retinopathy is a leading cause of blindness worldwide. The novel method will enable early diagnosis and treatment of the condition, potentially minimizing damage and saving vision.
In parallel, Holmen, a leading manufacturer in the forest based sector, has entered into an investment and sub-licensing agreement with Melodea, by which Holmen has become one of the major shareholders in Melodea.
The capital is intended for the on-going Phase II clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; interim analysis is expected in H1 2014